FORM PTO-449
PATENT & TRADEMARK OFFICEU.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
OCO1000KQSERIAL NO.:
09/904,263INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
Rybak et al.FILING DATE:
July 11, 2001GROUP:
1642

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
ALH	AA	5,985,263	11/16/99	Lee et al.	424	85.2	
ALH	AB	5,951,974	09/14/99	Gilbert et al.	424	85.7	
ALH	AC	5,908,621	06/01/99	Glue et al.	424	85.7	
ALH	AD	4,766,106	08/23/88	Katre et al.	514	12	
ALH	AE	5,776,897	07/07/98	Lewis et al.	514	12	
ALH	AF	5,766,582	06/16/98	Yuen et al.	424	85.7	
ALH	AG	5,762,923	06/09/98	Gross et al.	424	85.7	
ALH	AH	5,382,427	01/17/95	Plunkett et al.	424	85.2	
ALH	AI	4,917,888	04/17/90	Katre et al.	424	85.91	
ALH	AJ	4,897,471	01/30/90	Stabinsky	536	27	
ALH	AK	4,695,623	09/22/87	Stabinsky	530	351	
ALH	AL	4,530,901	07/23/85	Weissmann	435	70	
ALH	AM	4,492,537	01/08/85	Awerkamp	417	404	
ALH	CE	5,711,944	1/27/98	Gilbert et al.	424	85.7	
ALH	CF	5,766,897	06/16/98	Braxton	435	172.1	
ALH	CG	6,363,162 B1	03/26/02	Rybak et al.	514	2	
ALH	CH	2001/0053548 A1	08/09/01	Rybak et al.	435	367	

FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
ALH	AN	0 236 987 B1	12/28/94	EPO				
ALH	AO	0 809 996 A2	12/03/97	EPO				
ALH	AP	0 593 868 A1	04/27/94	EPO				
ALH	AQ	WO 99/48535	30/09/99	WIPO				
ALH	AR	0 510 356 A1	10/28/92	EPO				
ALH	CD	WO95/13090	05/18/95	WIPO				
ALH	CL	WO98/48840	05/11/98	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ALH	AS	Kantarjian et al., "Treatment of Chronic Myelogenous Leukemia: Current Status and Investigational Options," Blood 87 :8 pp. 3069-3081, April 15, 1996						
ALH	AT	Hehlman et al., "Randomized Comparison of Interferon- α With Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia," Blood 84 :12 pp. 4064-4077, December 15, 1994						
ALH	AU	Kantarjian et al., "Chronic Myelogenous Leukemia: A Concise Update," Blood 82 :3 pp. 691-703, August 1, 1993						
ALH	AV	Nicolaou et al., "Total Synthesis of Taxol. 1. Retrosynthesis, Degradation, and Reconstitution," J. Am. Chem. Soc. 117 pp. 624-633, 1995						
	AW	Hasford, et al. "Interferon- α and Hydroxyurea in Early Chronic Myeloid Leukemia: A Comparative Analysis of the Italian and German Chronic Myeloid Leukemia Trials With Interferon- α ,"						
ALH	AX	Ozer et al., "Prolonged Subcutaneous Administration of Recombinant $\alpha 2b$ Interferon in Patients with Previously Untreated Philadelphia Chromosome-Positive Chronic-Phase Chronic Myelogenous Leukemia: Effect on Remission Duration and Survival: Cancer and Leukemia Group B Study 8583," Blood 82 :10 pp. 2975-2984, November 15, 1993						
ALH	AY	Ohnishi et al., "A Randomized Trial Comparing Interferon- α With Busulfan for Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase," Blood 86 :3 pp. 906-916, August 1, 1995						

Anne L. Sullivan 1/27/03

RECEIVED
NOV 08 2002
TECH CENTER 1600/2900



FORM PT-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
OCO1000KQ

SERIAL NO.:

09/904, 263

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT:
Rybak et al.FILING DATE:
July 11, 2001GROUP:
1642


AZ	Creagon et al., "Randomized, Surgical Adjuvant Clinical Trial of Recombinant Interferon Alfa-2a in Selected Patients With Malignant Melanoma," Journal of Clinical Oncology, 13 :13 pp. 2776-2783 November 1995
BA	Bergmann et al., "Daily Alternating Administration of High-Dose Alpha-2b-Interferon and Interleukin-2 Bolus Infusion in Metastatic Renal Cell Cancer," Cancer 72 :5, pp. 1735-1742 September 1, 1993
BB	Umeda et al., "Phase II Study of Alpha Interferon on Renal Cell Carcinoma," Cancer 58 :1231-1235, September 15, 1986
BC	Sokal et al., "Preferential Inhibition by Cytarabine of CFU-GM From Patients With Chronic Granulocytic Leukemia," Cancer 59 :197-202, January 1, 1987
BD	Fleming et al., "One-Sample Multiple Testing Procedure for Phase II Clinical Trials," Biometrics 38 :143-151 March 1982
BE	Rosenberg, et al., "Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients," Ann. Surg. 210 :4 pp. 474-485, 1989
BF	Kantarjian et al., "Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon- α Therapy," Ann Intern Med. 122 :254-261, 1995
BG	Talpaz et al., "Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Internal Medicine, 114 :7 April 1, 1991
BH	Négrier et al., "Intensive Regimen of Cytokines with Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinoma," Journal of Immunotherapy, 17 :62-68 1995
BI	Goldman, "Optimizing Treatment for Chronic Myeloid Leukemia," The New England Journal of Medicine, 337 :4, pp. 270-271, July 24, 1997
BJ	Guilhot, et al., "Interferon Alfa-2b Combined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia," The New England Journal of Medicine, 337 :4 pp. 223-229, 1997.
BK	The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine, 330 :12 pp.820-825, March 24, 1994
BL	Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progressive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13 :2 pp. 497-501 February 1995
BM	Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14 : 1 pp. 7-17, January 1996
BN	Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon- α 2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990
BO	Alfonso Gennaro, "Antineoplastic and Immunoactive Drugs," Remington's 18 th Ed., 1990
BP	Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patients with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract
BQ	Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343 :913-914 April 9, 1994
BR 1	Deprés-Brummer et al., "A Phase II Study of Ambulatory Chronomodulated High Dose Interferon (IFN α 2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15 :248, March 1996
BR 2	Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15 :248, March 1996
BR 3	Gitlitz et al., "Fluoropyrimidines Plus Interleukin-2 and Interferon- α in the Treatment of Metastatic Renal Cell Carcinoma: The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15 :248, March 1996
BS	P. Sagaster et al., "Randomised Study Using IFN- α versus IFN- α plus coumarin and cimetidine for treatment of advanced renal cell cancer," Annals of Oncology 6 :999-1003, 1995

Anne L. Alleran 1/27/03

RECEIVED

NOV 08 2002

TECH CENTER



FORM PT-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
OCO1000KQSERIAL NO.:
09/904,203INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
Rybak et al.FILING DATE:
July 11, 2001GROUP:
1642

(Use several sheets if necessary)

ALH	BT	D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," <i>Quality of Life Research</i> 6:103-108, 1997
ALH	BU	Sewa S. Legha, "The Role of Interferon Alfa in the Treatment of Metastatic Melanoma," <i>Seminars in Oncology</i> , 24:1 Suppl 4 (February) 1997, pp. S4-24-54-31
ALH	BV	W. Levens et al., "Long-Term Interferon Treatment in Metastatic Renal Cell Carcinoma," <i>Eur Urol.</i> 16:378-381, 1989
ALH	BW	Janice P. Dutcher, et al., "Outpatient Subcutaneous Interleukin-2 and Interferon-Alpha for Metastatic Renal Cell Cancer: Five-Year Follow-up of the Cytokine Working Group Study," <i>The Cancer Journal from Scientific American</i> 3:3 May/June 1997
ALH	BX	Talpaz et al, "Phase I Study Of Polyethylene Glycol (PEG) Interferon Alpha-2B (Intron-A) in CML Patients", <i>Blood</i> , Volume 92, Issue 10, Suppl. 1 part 1-2, 11/15, 1998, pp. 251A
ALH	BY	Talpaz et al, "Phase I Study Of Pegylated-Interferon α -2A (PEGASYS™) In Patients With Chronic Myelogenous Leukemia (CML)", <i>Blood</i> , Vol. 94, Issue 10, Suppl. 1, part 1, 11/15, 1999, pp.530A.
ALH	BZ	Walther P.J. et al., "Treatment of Metastatic Renal Cell Carcinoma (RCC) with Continuous Infusion 5-Fluorouracil and Interferon Alpha-2A in the Home Setting: A Phase I-II Trial", <i>Proceedings of the American Urological Association</i> , Vol. 155, May 1996 Supplement, p. 388A.
ALH	CA	Gebrosky et al., "Treatment of Renal Cell Carcinoma with 5-Fluorouracil and Alfa-Interferon", <i>Urology</i> , 50 (6) 1997, pp. 863-868.
ALH	CB	Atzpodien J. et al., "Interleukin-2 in Combination with Interferon- α and 5-Fluorouracil for Metastatic Renal Cell Cancer", <i>European Journal of Cancer</i> , Vol. 29A, Suppl. 5, 1993, pp. S6-S8.
EXAMINER	Anne L. Allerson	
	DATE CONSIDERED 1/27/03	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

29132_1

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900